Michelle Hessen, OD, spoke about the results of a new study evaluating the efficacy of cyclosporine ophthalmic solution 0.09% in patients with dry eye.

With nearly 210 million individuals affected by dry eye syndrome globally, the demand for effective treatment solutions has surged significantly. The condition is particularly prevalent among aging ...

Restasis, AbbVie) at baseline,” Johnston said. Patients both with and without meibomian gland dysfunction (MGD) had been taking CsA 0.05% for at least 3 months, according to the study ...

Late last week, Allergan announced it had sold a group of US patents for its $1.5 billion-a-year ophthalmology blockbuster Restasis (cyclosporine) to the Saint Regis Mohawk Tribe. In the bizarre ...

Lying in wait at the moment are well-entrenched therapies like Novartis' Xiidra (lifitegrast) and AbbVie's Restasis (cyclosporine), which are not considered to be particularly effective and have ...

Figure 2 provides a birds-eye view of the current and future trends in the management of severe OSD. Current management may not completely restore the functions and structure of the ocular surface ...

After hours: 14 March at 7:58:28 pm GMT-4 Loading Chart for ABBV ...

Pre-Market: 6:39:20 a.m. EDT Loading Chart for ABBV ...

Pre-market: 8:01:29 am GMT-4 Loading Chart for ABBV ...

After hours: 11 March at 19:58:54 GMT-4 Loading Chart for ABBV ...